Additionally, our findings indicate a potential interplay between PSMA expression and autophagy in prostate cancer cells, suggesting that combining PSMA-targeted therapies with autophagy inhibitors or modulators may improve treatment efficacy and patient outcomes. Here, FOLH1 is linked to prostate cancer.